AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
med-marvels
/
details

CAR T-cell Therapy at Narayana Health City Shows Remarkable Success in Cancer Treatment

NextEdge Admin

25 May 2024

3 min 21 sec

Narayana Health City in Bangalore has achieved a breakthrough in cancer treatment through the successful application of CAR T-cell therapy, signifying a significant advancement in the battle against cancer. Developed by IMMUNEEL in Bangalore, this state-of-the-art immunotherapy modifies a patient’s T-cells to enhance their ability to identify and combat cancerous cells.

CAR T-cell therapy, also referred to as Chimeric Antigen Receptor T-cell therapy, has demonstrated remarkable effectiveness in addressing specific blood cancers such as leukemia and lymphoma. The procedure involves the genetic modification of T-cells to specifically target and eradicate cancer cells.

Dr. Sharat Damodar, Senior Consultant Haematologist and Head of Adult BMT at Narayana Health City, remarked, “CAR T-Cell therapy has revolutionized cancer treatment by providing a lifeline to patients who have exhausted conventional options.” He highlighted a case illustrating the therapy’s potential to induce lasting remission in relapsed lymphoma.

The recent approval of CAR T-cell therapy by the Drug Controller General of India (DCGI) for commercial use is a significant milestone for patients grappling with relapsed and refractory cancers. Hamza Khan, a 42-year-old resident of Bangalore, became the inaugural patient in South India to undergo this groundbreaking treatment for relapsed follicular lymphoma.

Hamza’s cancer journey commenced during the COVID-19 pandemic in 2020. Despite undergoing multiple chemotherapy rounds and rituximab maintenance, his cancer relapsed in February 2022, leading to a dire prognosis. Standard treatments, including chemotherapy and autologous stem cell transplant, proved futile, exacerbated by a severe COVID-19 infection.

Selected for CAR T-cell therapy in September 2022, Hamza underwent the procedure under the care of Dr. Sharat Damodar, with successful administration in November 2022. Experiencing minimal side effects, Hamza achieved remission, surpassing the significant milestone of one-year post-treatment without relapse.

Narayana Health City continues to lead the charge in such advancements, ensuring that cutting-edge treatment options are accessible within India. The hospital’s Facility Director expressed immense pride in the strides made in cancer treatment, emphasizing their commitment to providing the best care and hope to patients through innovative therapies like CAR T-cell therapy.